Jaguar Animal Health, which is developing an animal formulation of its parent's approved diarrhea treatment, raised $20 million by offering 2.86 million shares at $7, the low end of its originally proposed $7 to $9 range. Jaguar Animal Health listed on the NASDAQ under the symbol JAGX. Aegis Capital acted as a sole bookrunner on the deal.
